SK942004A3 - 4-(benzylidene-amino)-3-(methylsulfanyl)-4H-(1,2,4) triazin-5-one derivatives having a PDE-IV inhibiting and TNF-antagonistic effect for the treatment of cardiac diseases and allergies - Google Patents

4-(benzylidene-amino)-3-(methylsulfanyl)-4H-(1,2,4) triazin-5-one derivatives having a PDE-IV inhibiting and TNF-antagonistic effect for the treatment of cardiac diseases and allergies Download PDF

Info

Publication number
SK942004A3
SK942004A3 SK94-2004A SK942004A SK942004A3 SK 942004 A3 SK942004 A3 SK 942004A3 SK 942004 A SK942004 A SK 942004A SK 942004 A3 SK942004 A3 SK 942004A3
Authority
SK
Slovakia
Prior art keywords
och
formula
solvates
compounds
och3
Prior art date
Application number
SK94-2004A
Other languages
English (en)
Slovak (sk)
Inventor
Hans-Michael Eggenweiler
Michael Wolf
Norbert Beier
Joachim Leibrock
Pierre Schelling
Michael Gassen
Thomas Ehring
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2001135009 external-priority patent/DE10135009A1/de
Priority claimed from DE2001156229 external-priority patent/DE10156229A1/de
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SK942004A3 publication Critical patent/SK942004A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
SK94-2004A 2001-07-18 2002-06-19 4-(benzylidene-amino)-3-(methylsulfanyl)-4H-(1,2,4) triazin-5-one derivatives having a PDE-IV inhibiting and TNF-antagonistic effect for the treatment of cardiac diseases and allergies SK942004A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE2001135009 DE10135009A1 (de) 2001-07-18 2001-07-18 Triazinderivate
DE2001156229 DE10156229A1 (de) 2001-11-15 2001-11-15 Triazinderivate
PCT/EP2002/006742 WO2003008392A1 (de) 2001-07-18 2002-06-19 4-(benzyliden-amino)-3-(methylsulfanyl) -4h-(1, 2, 4) triazin-5-on derivate mit pde -iv hemmender und tnf-antagonistischer wirkung zur behandlung von herzkrankheiten und allergien

Publications (1)

Publication Number Publication Date
SK942004A3 true SK942004A3 (en) 2004-06-08

Family

ID=26009725

Family Applications (1)

Application Number Title Priority Date Filing Date
SK94-2004A SK942004A3 (en) 2001-07-18 2002-06-19 4-(benzylidene-amino)-3-(methylsulfanyl)-4H-(1,2,4) triazin-5-one derivatives having a PDE-IV inhibiting and TNF-antagonistic effect for the treatment of cardiac diseases and allergies

Country Status (18)

Country Link
US (1) US7485639B2 (pl)
EP (1) EP1406878B1 (pl)
JP (1) JP4546082B2 (pl)
KR (1) KR20040023655A (pl)
CN (1) CN1531529A (pl)
AT (1) ATE328875T1 (pl)
AU (1) AU2002354850B2 (pl)
BR (1) BR0211209A (pl)
CA (1) CA2453974C (pl)
CZ (1) CZ2004213A3 (pl)
DE (1) DE50207119D1 (pl)
ES (1) ES2266539T3 (pl)
HU (1) HUP0401115A3 (pl)
MX (1) MXPA04000538A (pl)
PL (1) PL366792A1 (pl)
RU (1) RU2004104945A (pl)
SK (1) SK942004A3 (pl)
WO (1) WO2003008392A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090105314A1 (en) * 2006-05-15 2009-04-23 Takeda Pharmaceutical Company Limited Pharmaceutical Agent
JP5775299B2 (ja) * 2007-04-10 2015-09-09 アンセルム（アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） 血管障害治療のためのｍｒｐ４阻害剤
EA201591360A1 (ru) 2013-02-19 2016-03-31 Пфайзер Инк. Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
JP6713982B2 (ja) 2014-07-24 2020-06-24 ファイザー・インク ピラゾロピリミジン化合物
AP2017009744A0 (en) 2014-08-06 2017-02-28 Pfizer Imidazopyridazine compounds
CN104997766A (zh) * 2015-08-22 2015-10-28 南京华宽信息咨询中心 一种治疗或预防慢性心衰药物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036632A (en) * 1966-04-16 1977-07-19 Bayer Aktiengesellschaft Herbicidal agents
CH495110A (de) * 1966-04-16 1970-08-31 Bayer Ag Herbizides Mittel
US4346220A (en) * 1966-11-28 1982-08-24 E. I. Du Pont De Nemours And Company 1,2,4-Triazin-5-ones
US3905801A (en) * 1966-11-28 1975-09-16 Du Pont Substituted 1,2,4-triazine-5-ones as herbicides
US4345220A (en) * 1980-02-12 1982-08-17 The United States Of America As Represented By The Secretary Of The Air Force High power microwave generator using relativistic electron beam in waveguide drift tube
JPS61134389A (ja) * 1984-12-04 1986-06-21 Shionogi & Co Ltd トリアジノン誘導体および抗潰瘍剤
DE19533975A1 (de) 1995-09-14 1997-03-20 Merck Patent Gmbh Arylalkyl-diazinone
EP0927171B1 (en) 1996-09-16 2002-02-20 Du Pont Pharmaceuticals Company Pyrazinones and triazinones and their derivatives thereof
US6290929B1 (en) * 2000-07-28 2001-09-18 The Procter & Gamble Company Cancer treatment

Also Published As

Publication number Publication date
ES2266539T3 (es) 2007-03-01
CA2453974C (en) 2011-01-11
AU2002354850B2 (en) 2008-02-28
KR20040023655A (ko) 2004-03-18
HUP0401115A3 (en) 2005-11-28
ATE328875T1 (de) 2006-06-15
CA2453974A1 (en) 2003-01-30
JP4546082B2 (ja) 2010-09-15
EP1406878A1 (de) 2004-04-14
RU2004104945A (ru) 2005-07-10
HUP0401115A2 (hu) 2004-09-28
US7485639B2 (en) 2009-02-03
CN1531529A (zh) 2004-09-22
CZ2004213A3 (cs) 2004-06-16
EP1406878B1 (de) 2006-06-07
WO2003008392A1 (de) 2003-01-30
US20040176252A1 (en) 2004-09-09
PL366792A1 (pl) 2005-02-07
MXPA04000538A (es) 2004-05-04
DE50207119D1 (de) 2006-07-20
JP2004535468A (ja) 2004-11-25
BR0211209A (pt) 2004-07-13

Similar Documents

Publication Publication Date Title
US5750545A (en) Triazole derivative and pharmaceutical use thereof
JP4294960B2 (ja) 抗癌剤としてのサイクリン依存性キナーゼ阻害剤
JP2006524688A (ja) プロテインキナーゼのインヒビターとして有用なチアゾール
JP2009269932A (ja) プロテインキナーゼのインヒビターとして有用なチアゾール化合物
PL214701B1 (pl) Pochodna piperydyny, kompozycja farmaceutyczna zawierajaca te pochodna oraz zastosowanie lecznicze tej pochodnej
KR20040071252A (ko) 포스포디에스테르 ⅶ 억제제로서의 피롤로피리미딘
KR20050008817A (ko) 아릴 옥심
FI79104B (fi) Foerfarande foer framstaellning av ett nytt terapeutiskt anvaendbart dihydropyridinderivat.
CZ20032491A3 (cs) Ftalazinonpiperidinové deriváty
SK112893A3 (en) Benzofuran derivatives, method of their preparation and pharmaceutical compositions containing them
SK18932000A3 (sk) Derivát arylalkanoylpyridazínu, spôsob jeho prípravy a farmaceutický prostriedok, ktorý ho obsahuje
EP2882715B1 (en) Pyrazole derivatives and their use as lpar5 antagonists
SK942004A3 (en) 4-(benzylidene-amino)-3-(methylsulfanyl)-4H-(1,2,4) triazin-5-one derivatives having a PDE-IV inhibiting and TNF-antagonistic effect for the treatment of cardiac diseases and allergies
CZ390992A3 (en) Pyrimidine derivatives, process of their preparation and use as substances for increase of anti-tumor activity
RU2532376C2 (ru) Агенты, ингибирующие р38 киназу
CZ20031860A3 (cs) Derivát benzoylpyridazinu, způsob jeho přípravy, jeho použití a farmaceutický prostředek, který ho obsahuje
US4343801A (en) 1,2,4-Triazine derivatives, and their production and use
US5108998A (en) Cardiotonic thiadiazine derivatives
WO2003008373A1 (de) Tyrosinhydrazide
EP4678234A1 (en) Antagonist heterocyclic compounds involved in the cgas-sting route
CZ200212A3 (cs) Derivát benzoylpyridazinu, způsob jeho přípravy a farmaceutický prostředek, který ho obsahuje
AU2017348598B2 (en) Crystalline form of (1R,2R)-2-[4-(3-methyl-1H-pyrazol-5-yl)benzoyl]-N- (4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3- yl)cyclohexanecarboxamide
DE10156229A1 (de) Triazinderivate
ZA200401276B (en) 4-(benzylidene-amino)-3-(methylsulfanyl)-4H-1,2,4-triazin-5-one derivatives having a PDE IV-inhibiting and TNF-antagonistic action for the treatment of heart diseases and allergies.
HK1142891B (en) Pyrimidinyl pyridazinone derivates